NIH Reverses Cuts in Grants

WASHINGTON—The National Institutes of Health has halted further cuts in the size of new research grants, an action it took in response to a proposed cut in funding for this year, and begun to restore funds to grants that were reduced. On February 25 NIH reversed a decision, made January 21, that took between 4 and nearly 20 percent from each grant to make sure the agency did not run out of money before the end of the fiscal year September 30. The Reagan administration has proposed that $33

Written byRon Cowen
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

On February 25 NIH reversed a decision, made January 21, that took between 4 and nearly 20 percent from each grant to make sure the agency did not run out of money before the end of the fiscal year September 30. The Reagan administration has proposed that $334 million of NIH's $6.2 billion budget for this year be held until next year, although Congress is unlikely to go along with such a reduction. NIH Deputy Director William Raub said that congressional approval later this spring would require grants awarded in the final quarter of the year to be cut by "as much as 40 percent."

Biomedical and university groups last month threatened to sue the administration on the grounds that the plan violated the will of Congress. But James Miller, director of the Office of Management and Budget, signaled the administration's retreat February 24 in a letter to Health and ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies